Company intelligence / Profile preview

Paramount Capital

New York, New York, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Paramount Capital and its related entities have financed, managed, and helped develop dozens of innovative biotech companies, some of whose candidates have reached commercial stage and achieved regulatory approval (e.g. abiraterone acetate for prostate cancer, retinoic acid for leukemia, and others developed by companies it helped create); several portfolio drugs have made significant impact in their respective indications.

Therapeutic areas: EndocrinologyRheumatologyPulmonologyInfectious DiseasesPsychiatryOncology
Modalities: Small moleculeMonoclonal antibodyGene therapyBiologicVaccineVarious others
Industry: Investors

Partnerships

Whalehaven Capital FundRockmore CapitalRamius CapitalNYC Emerging Industries Fund (advisory)

Beyond the preview

Go deeper on Paramount Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paramount Capital.

Explore the full profile